Brief: Natco Pharma Submits ANDA For Risdiplam For Oral Solution

Natco Pharma

21/11/2024 09:38

Nov 21 (Reuters) - Natco Pharma Ltd  NATP.NS :
    * SUBMITS ANDA FOR RISDIPLAM FOR ORAL SOLUTION
    * SUBMITTED ANDA WITH US FDA FOR GENERIC VERSION OF EVRYSDI
(RISDIPLAM)
    * EXPECTS TO BE ELIGIBLE FOR 180 DAYS OF SHARED MARKETING
EXCLUSIVITY

Source text:  ID:nBSE3BWpw7 
Further company coverage:  NATP.NS 

 ((Reuters.Briefs@thomsonreuters.com;;))